Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Changpu Yu"'
Autor:
Priyanka Gupta, Haley Neff-LaFord, Kelly Hensley, Sean Allred, Andres Forero-Torres, Byron Kwan, Megan Ramirez, Steven Jin, Changpu Yu, Serena Wo, Jessica Simmons, Christina Zuch de Zafra, Shawna Hengel, Heather Van Epps
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/5b55852b95754d28bcc8588ebe7f1c9a
Autor:
Dennis R. Benjamin, Eric J. Feldman, Che-Leung Law, Peter D. Senter, Sa A. Wang, Maitrayee Goswami, Timothy S. Lewis, Mechthild Jonas, Weiping Zeng, Ivan J. Stone, Martha E. Anderson, Michelle Ulrich, Kerry Klussman, Django Sussman, Ashley Cronkite, Lucy Pan, John Valliere-Douglass, Lori Westendorf, Roland B. Walter, Changpu Yu, May Kung Sutherland, Fu Li
Gating strategy, primary AML cytotoxicity assay,additional cell liens for pH2AX assay and caspase assay, and h7G3ec antibody sequence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d6621500ceec28e5ffa45ca4f5d714e
https://doi.org/10.1158/1535-7163.22505200
https://doi.org/10.1158/1535-7163.22505200
Autor:
Dennis R. Benjamin, Eric J. Feldman, Che-Leung Law, Peter D. Senter, Sa A. Wang, Maitrayee Goswami, Timothy S. Lewis, Mechthild Jonas, Weiping Zeng, Ivan J. Stone, Martha E. Anderson, Michelle Ulrich, Kerry Klussman, Django Sussman, Ashley Cronkite, Lucy Pan, John Valliere-Douglass, Lori Westendorf, Roland B. Walter, Changpu Yu, May Kung Sutherland, Fu Li
Treatment choices for acute myelogenous leukemia (AML) patients resistant to conventional chemotherapies are limited and novel therapeutic agents are needed. IL3 receptor alpha (IL3Rα, or CD123) is expressed on the majority of AML blasts, and there
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac8020bf88554cef4d7229c4d038ea4f
https://doi.org/10.1158/1535-7163.c.6537988.v1
https://doi.org/10.1158/1535-7163.c.6537988.v1
Autor:
Steven Jin, Shawna Hengel, Christina L. Zuch de Zafra, Byron Hua Kwan, Sean Allred, Andres Forero-Torres, Megan Ramirez, Haley Neff-LaFord, Changpu Yu, Serena Wo, Jessica K. Simmons, Heather Van Epps, Priyanka Gupta, Kelly Hensley
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPD-1/PD-L1 immune checkpoint inhibitors have transformed oncology, but a significant unmet need persists for patients with relapsed/refractory tumors following PD-1/PD-L1 treatment. PD-L1 is expressed in patients across a broad spectrum of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf5354dce62227e2df08699edde794af
https://doaj.org/article/5b55852b95754d28bcc8588ebe7f1c9a
https://doaj.org/article/5b55852b95754d28bcc8588ebe7f1c9a
Autor:
Ashley Cronkite, Peter D. Senter, Eric J. Feldman, Lucy Yan Pan, Maitrayee Goswami, Fu Li, May Kung Sutherland, Weiping Zeng, John F. Valliere-Douglass, Lori Westendorf, Michelle Ulrich, Che Leung Law, Sa A. Wang, Dennis Benjamin, Kerry Klussman, Changpu Yu, Django Sussman, Roland B. Walter, Ivan Stone, Timothy S. Lewis, Mechthild Jonas, Martha Anderson
Publikováno v:
Molecular Cancer Therapeutics. 17:554-564
Treatment choices for acute myelogenous leukemia (AML) patients resistant to conventional chemotherapies are limited and novel therapeutic agents are needed. IL3 receptor alpha (IL3Rα, or CD123) is expressed on the majority of AML blasts, and there
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f8651b66cbdcc3ebe56b3b4692dd2ef
https://doi.org/10.1158/1535-7163.mct-17-0742
https://doi.org/10.1158/1535-7163.mct-17-0742
Autor:
Hong Li, Clark Henderson, Christine O'Day, Phoenix A. Ho, Heather A. Van Epps, Changpu Yu, David R. Taft
Publikováno v:
Blood. 138:1197-1197
Patients with relapsed/triple class refractory (refractory to a proteasome inhibitor, immunomodulatory drug or anti-CD38 antibody) multiple myeloma (MM) have limited treatment options. Versatile therapies, such as unconjugated antibodies (Abs), that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17123d2185fa1497cbbf6aad9a1a123b
https://doi.org/10.1182/blood-2021-150866
https://doi.org/10.1182/blood-2021-150866
Autor:
Changpu Yu, Maria Corinna Palanca-Wessels, Brian Schimpf, Dennis Benjamin, Heather A. Van Epps, Maureen Ryan, Heather Kostner, Kristine A. Gordon, Brad Meyer
Patients with relapsed/refractory B-cell malignancies such as non-Hodgkin lymphoma (B-NHL) or acute lymphoblastic leukemia have a poor prognosis. Despite measurable clinical activity with new targeted therapies, many patients do not achieve a complet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc059f6cc3f1db8edcd812047f417dbd
https://europepmc.org/articles/PMC5669207/
https://europepmc.org/articles/PMC5669207/
Autor:
Heather Kostner, Changpu Yu, Leia M. Smith, Julie A. McEarchern, Kristine A. Gordon, M C Ryan, Che-Leung Law, Albina Nesterova, May Kung Sutherland, Kristine M. Kim, Steven Duniho, Martha Anderson
Publikováno v:
British Journal of Cancer
Background: CD70 is an ideal target for antibody-based therapies because of its aberrant high expression in renal carcinomas and non-Hodgkin lymphomas and its highly restricted expression in normal tissues. The expression profiling of CD70 in carcino
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31bf792b0b605debb79db28ca4e495dd
http://europepmc.org/articles/PMC2938259
http://europepmc.org/articles/PMC2938259
Autor:
Eileen Turcott, Ethan W. Ojala, May Kung Sutherland, John A. Latham, David G. Winkler, John Skonier, Diana Shpektor, Changpu Yu, James C. Geoghegan
Publikováno v:
Journal of Biological Chemistry. 280:2498-2502
High bone mass diseases are caused both by activating mutations in the Wnt pathway and by loss of SOST, a bone morphogenetic protein (BMP) antagonist, leading to the activation of BMP signaling. Given the phenotypic similarity between mutations that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db290ff9e00f30788375f7aa32143aec
https://doi.org/10.1074/jbc.m400524200
https://doi.org/10.1074/jbc.m400524200
Autor:
Eileen Turcott, David G. Winkler, John Skonier, John A. Latham, James C. Geoghegan, May Kung Sutherland, Changpu Yu
Publikováno v:
Bone. 35:828-835
A null mutation in the SOST gene is associated with sclerosteosis, an inherited disorder characterized by a high bone mass phenotype. The protein product of the SOST gene, sclerostin, is a bone morphogenetic protein (BMP) antagonist that decreases os
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dd0825a56fcc0c837a91748c09d210a
https://doi.org/10.1016/j.bone.2004.05.023
https://doi.org/10.1016/j.bone.2004.05.023